Loading...
Intellipharmaceutics International Inc.
IPCIF•PNK
Healthcare
Biotechnology
$0.15
$0.00(0.00%)

Over the past four quarters, Intellipharmaceutics International Inc. demonstrated steady revenue growth, increasing from $29682.00 in Q4 2023 to $68718.00 in Q3 2024. Operating income reached -$1.79M in Q3 2024, maintaining a consistent -2601% margin over recent quarters. Despite fluctuations in R&D and SG&A expenses, EBITDA remained robust at -$1.75M, reflecting operational efficiency. Net income dropped to -$1.89M, with EPS at -$0.06. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan